Brief: REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
14/01/2025 12:52
Jan 14 (Reuters) - Regenxbio Inc RGNX.O :
* REGENXBIO AND NIPPON SHINYAKU ANNOUNCE EXCLUSIVE
PARTNERSHIP TO
DEVELOP AND COMMERCIALIZE RGX-121 AND RGX-111 FOR MPS DISEASES
* REGENXBIO INC - TO RECEIVE $110 MILLION UPFRONT, UP TO
$700
MILLION IN MILESTONES
* REGENXBIO INC - RETAINS RIGHTS TO RGX-121 PRIORITY REVIEW
VOUCHER
Source text: ID:nPn5BHy6Wa
Further company coverage: RGNX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nippon Shinyaku
See all newsTable: Nippon Shinyaku -Q1 group results (IFRS)
Brief: Elixirgen Therapeutics And Nippon Shinyaku Enter Into An Option Agreement For The Development And Commercialization Of Exg-7001 For Duchenne Muscular Dystrophy
Table: Nippon Shinyaku -2025/26 group results (IFRS)
Table: Nippon Shinyaku -2025/26 parent results
Table: Nippon Shinyaku -9-MTH group results (IFRS)